Solventum (NYSE:SOLV) beats Q3 2026 sales expectations
Solventum (SOLV) reported Q3 2026 revenue of $1.95 billion, beating estimates by 0.9% but down 7% year-on-year. Adjusted EPS of $1.45 exceeded expectations by 7.9%. The company raised full-year EPS guidance to $7.25. Operating margin fell to 3.5%, while free cash flow improved to $97 million. Organic revenue declined 2.8% year-on-year.
How this was made

The 30-second read
Why it matters
The earnings beat and guidance raise could prompt short-term buying, but margin compression may limit upside.
Market read
Earnings release is a primary corporate event with modest positive market relevance.
What to watch
Free cash flow turned positive and guidance raise may be offset by margin weakness.
Background
Solventum reported Q3 2026 results with revenue of $1.95B versus $1.93B estimate and adjusted EPS of $1.45 versus $1.34 estimate.
Ticker impact
Q3 2026 earnings beat revenue and EPS estimates and raised full-year EPS guidance.
likely modest buying pressure as the market prices in the EPS beat and guidance raise.
The earnings release is the first report of the numbers; beat is small and guidance increase modest, so impact is expected to be limited but positive.
Market effects
Provides a modest positive signal for the specialty chemicals sector.
North American markets may see slight uplift in related stocks.
Limited global impact; primarily relevant to US investors.
Counterpoint
The beat is narrow and operating margin collapsed, suggesting deeper operational issues.
Key entities
- CompanySolventum
Specialty chemicals producer listed on NYSE.



